Choosing a Statin Around a Drug That Blocks Most of Them
Every statin option interacts with ritonavir to some degree — the real decision is which interaction is most predictable and most manageable, not which one to pretend doesn't exist.
R.G., a 58-year-old man, retired from twenty-six years as a city bus driver last spring and has spent most of the time since learning to fish seriously, a hobby he says he never had the schedule for during his working years. He has been on a darunavir/ritonavir-based regimen for over a decade after cycling through several earlier options complicated by tolerability issues, and has remained virologically suppressed on it without difficulty. A routine lipid panel at his last visit returned an LDL cholesterol of 168 mg/dL, and combined with his age and a family history of early coronary disease — his father had a heart attack at 54 — his cardiologist has recommended starting a statin. He has no history of muscle pain or prior statin exposure of any kind, and his creatine kinase drawn at the same visit is within normal limits, giving the team a clean baseline before anything new is started.
The complication is his own regimen. Ritonavir is a potent inhibitor of CYP3A4, the enzyme responsible for metabolizing most commonly prescribed statins, and that inhibition can raise statin levels enough to meaningfully increase myopathy and rhabdomyolysis risk — simvastatin and lovastatin are considered contraindicated outright with a ritonavir-boosted regimen for this reason. But the interaction isn't uniform across the whole drug class. Pitavastatin undergoes minimal CYP3A4 metabolism and is largely spared. Rosuvastatin avoids CYP3A4 as its primary pathway but is cleared substantially through the OATP1B1 and BCRP transporters, both of which ritonavir also inhibits, raising its levels through a separate mechanism. Atorvastatin, the most widely prescribed and outcomes-studied statin in general use, is partly but not entirely CYP3A4-dependent, leaving it neither cleanly safe nor flatly contraindicated. His LDL target and his own regimen sit at the center of a real choice among three imperfect options, not a search for one interaction-free answer — and given his ten-year history of tolerability problems with earlier antiretroviral regimens, the team is also mindful of not repeating that pattern with whichever statin gets chosen this time.
HIV clinic, cardiovascular risk visit
Pitavastatin is the cleanest mechanistic answer to what ritonavir is actually doing here. It undergoes minimal CYP3A4 metabolism, so the enzyme ritonavir potently inhibits barely touches its clearance in the first place. Current drug-interaction guidance names it preferred for exactly this scenario. I'd start there.
The mechanism argument is sound, and I'm not disputing pitavastatin's interaction profile.
My concern is practical rather than pharmacologic: pitavastatin is far less commonly stocked and prescribed than rosuvastatin, and a drug his pharmacy has to special-order carries its own real risk of a gap in therapy. Rosuvastatin does interact with ritonavir — through OATP1B1 and BCRP transport inhibition rather than CYP3A4 — but that interaction is well-characterized, with an established lower starting dose. A familiar drug with a known adjustment may serve him more reliably than the theoretically cleaner option.
I'd widen the frame one more step before settling on either. His LDL and family history put him in a population where atorvastatin has the deepest outcomes evidence of any statin available — decades of cardiovascular-endpoint data neither of the other two options can fully match. It's partially, not entirely, CYP3A4-dependent, and real-world cohorts on boosted regimens have used it at capped, low starting doses without a high observed toxicity rate. I'll also say his risk picture isn't as urgent as his LDL number alone suggests — he quit smoking eight years ago, which has already meaningfully pulled his cardiovascular trajectory in the right direction, and that's part of why I'm comfortable not pushing atorvastatin as the priority pick today. I'm not arguing for it over pitavastatin so much as arguing it shouldn't be dismissed outright — but given the two of you have a genuinely interaction-minimal option on the table already, I won't push past a second choice here.
Agreed: pitavastatin started today, with dose-capped rosuvastatin documented in the chart as the specific fallback if access becomes an issue. Repeat lipid panel and liver enzymes planned at 6 and 12 weeks, standard for any new statin start, with no change planned to his ART regimen.